Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
2017 · Blood · 1,419 citations
https://doi.org/10.1182/blood-2017-04-779405
A
Arthur E. Frankel
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
149
Papers
6.5K
Citations
40
h-index
87
i10-index
Arthur E. Frankel is an academic researcher. The author has contributed to research in topics: Toxin Mechanisms and Immunotoxins & Transgenic Plants and Applications & Monoclonal and Polyclonal Antibodies Research. The author has an h-index of 40, co-authored 127 publications.
ORCID: 0000-0001-6201-8802Papers by this author
worksSafety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial
2015 · Blood · 72 citations
https://doi.org/10.1182/blood.v126.23.323.323
Digoxin Plus Trametinib Therapy Achieves Disease Control in BRAF Wild-Type Metastatic Melanoma Patients
2017 · Neoplasia · 45 citations
https://doi.org/10.1016/j.neo.2017.01.010
1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes induce autophagic cell death in estrogen receptor negative breast cancer
2010 · BMC Cancer · 19 citations
https://doi.org/10.1186/1471-2407-10-669
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat